Cargando…
Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring
BACKGROUND/AIMS: Evidence on predictors of primary nonresponse (PNR), and secondary loss of response (SLR) to anti-tumor necrosis factor (anti-TNF) agents in inflammatory bowel disease is scarce from Asia. We evaluated clinical/biochemical/molecular markers of PNR/SLR in ulcerative colitis (UC) and...
Autores principales: | Kumar, Peeyush, Vuyyuru, Sudheer K., Das, Prasenjit, Kante, Bhaskar, Ranjan, Mukesh Kumar, Thomas, David Mathew, Mundhra, Sandeep, Sahu, Pabitra, Venigalla, Pratap Mouli, Jain, Saransh, Goyal, Sandeep, Golla, Rithvik, Virmani, Shubi, Singh, Mukesh K., Sachdeva, Karan, Sharma, Raju, Dash, Nihar Ranjan, Makharia, Govind, Kedia, Saurabh, Ahuja, Vineet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626021/ https://www.ncbi.nlm.nih.gov/pubmed/36926698 http://dx.doi.org/10.5217/ir.2022.00128 |
Ejemplares similares
-
High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India
por: Kante, Bhaskar, et al.
Publicado: (2023) -
Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022) -
Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study
por: Golla, Rithvik, et al.
Publicado: (2023) -
Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
por: Vuyyuru, Sudheer K., et al.
Publicado: (2021) -
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
por: Kamat, Nagesh, et al.
Publicado: (2022)